Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-pretreatment digoxin assays and developments in immunoanalyzers.

D A Armbruster1

  • 1LTC Medical Laboratories, Dallas TX, USA.

Clinical Laboratory Science : Journal of the American Society for Medical Technology
|February 6, 1997
PubMed
Summary

This study evaluated a new digoxin assay for the Abbott IMx analyzer, finding it reliable and suitable for routine clinical use. The assay demonstrated good precision and accuracy, with no significant interference.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Some personal reflections on downsizing.

Clinical laboratory management review : official publication of the Clinical Laboratory Management Association·1998
Same author

On-site drug testing on the rise and growing strong.

MLO: medical laboratory observer·1997
Same author

The quintessence of quality in the clinical laboratory.

Clinical laboratory management review : official publication of the Clinical Laboratory Management Association·1995
Same author

Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.

Clinical chemistry·1995
Same author

Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs.

Clinical chemistry·1994
Same author

Method comparison of EMIT 700 and EMIT II with RIA for drug screening.

Journal of analytical toxicology·1994

Area of Science:

  • Clinical Chemistry
  • Immunoassay Technology
  • Therapeutic Drug Monitoring

Background:

  • Digoxin is a critical medication for managing cardiac arrhythmias.
  • Accurate therapeutic drug monitoring is essential for optimizing digoxin efficacy and minimizing toxicity.
  • Advancements in immunoassay technology aim to improve the speed and reliability of drug level testing.

Purpose of the Study:

  • To evaluate the performance of a new, non-pretreatment digoxin assay on the Abbott IMx analyzer.
  • To determine the assay's reliability and suitability for routine clinical use in long-term care facilities.
  • To compare the new assay's operational characteristics with existing immunoanalyzer generations.

Main Methods:

  • Assessed within-run and day-to-day precision and the limit of detection.

Related Experiment Videos

  • Evaluated the effect of digoxin-like immunoreactive factors and carryover.
  • Compared results from the new IMx digoxin assay against the Dade Stratus II digoxin test using patient serum samples.

    • Main Results:

    • The assay exhibited a limit of detection of 0.27 ng/mL and day-to-day precision between 3.4% and 5.9% CV.
    • Linear regression showed strong correlation with the reference method (r = 0.9776).
    • No significant interference was observed from digitoxin-like immunoreactive factors.

    Conclusions:

    • The Abbott IMx non-pretreatment digoxin assay meets manufacturer specifications.
    • The assay demonstrates favorable performance compared to other automated digoxin tests.
    • The evaluated digoxin assay is suitable for routine clinical application in therapeutic drug monitoring.